

Technical Data Sheet

Product Anti-MAP2 Purified

Cat. Number/Size **11-473-C025 0.025 mg** 

11-473-C100 0.1 mg

For Research Use Only.

Not for use in diagnostic or therapeutic procedures.

Antigen MAP2
Clone MT-08
Format Purified

Reactivity Pig, Human, Mouse

Application IP, WB, IHC-P, IHC-F, ICC, ELISA

Application details Immunohistochemistry (paraffin sections): Recommended dilution: 10 µg/ml; positive tissue: brain.

Immunohistochemistry (frozen sections): Positive tissue: murine brain.

Immunoprecipitation: Positive material: porcine brain. Western blotting: Positive control: porcine brain.

ELISA: Positive control: porcine brain.

Immunocytochemistry: Positive control: human neuroblastoma SH-SY5Y.

Isotype Mouse IgG1

Specificity The antibody MT-08 recognizes an epitope (aa 1375-1395) located in central domain of molecule

Microtubule Associated Protein 2ab (MAP2ab), an intracellular antigen.

Other names Microtubule-associated protein 2, MAP-2

Immunogen Microtubule protein (bovine brain) enriched for kinesin

Entrez Gene ID 4133
Gene name MAP2

NCBI Full Gene Name microtubule associated protein 2

UniProt ID P11137

Concentration 1 mg/ml

Preparation Purified by protein-A affinity chromatography.

Formulation Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Storage and handling Store at 2-8°C. Do not freeze.

Images and References www.exbio.cz

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Revision date: 2025-01-02